Lukas Scheibler Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Lukas Scheibler is Chief Research Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 68,299 shares of APLS, which is worth approximately $2.18 Million. The most recent transaction as insider was on Jan 28, 2022, when has been sold 642 shares (Common Stock) at a price of $38.59 per share, resulting in proceeds of $24,775. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 68.3K

0% 3M change

0% 12M change

Total Value Held $2.18 Million

LUKAS SCHEIBLER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 28 2022	SELL Payment of exercise price or tax liability	$24,775 $38.59 p/Share	642 Reduced 1.15%	55,090 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	26,051 Added 31.85%	55,732 Common Stock
Jan 21 2022	BUY Exercise of conversion of derivative security	$80,751 $26.73 p/Share	3,021 Added 9.24%	29,681 Common Stock
Jun 10 2021	SELL Open market or private sale	$205,020 $60.0 p/Share	3,417 Reduced 11.36%	26,651 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$32,450 $47.72 p/Share	680 Reduced 2.27%	29,290 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	9,375 Added 23.83%	29,970 Common Stock
Dec 08 2020	BUY Exercise of conversion of derivative security	$199,994 $26.73 p/Share	7,482 Added 26.65%	20,595 Common Stock

Lukas Scheibler

Chief Research Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account